An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate a variable dosing regimen with intravitreal ranibizumab
for the treatment of patients with neovascular age-related macular degeneration (AMD) in the
Prospective OCT Imaging of Patients with Neovascular AMD Treated with Intra-Ocular
Ranibizumab (PrONTO) study.